drugset / Trial / NCT07217860
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NaSingle-groupOpen-labelTreatment
Summary
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.
Timeline
- Start
- 2025-10-30
- Primary completion
- 2029-06
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azetukalner | Small molecule | 20 mg | Oral |